Drug Trial Radar · NCT06137482
A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Dec 6, 2023
Primary completion
Feb 11, 2025
Study completion Feb 11, 2025
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults. The aim of the study is to see how safe and tolerable REGN13335 is in healthy volunteers. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is present in the blood of study participants at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Healthy Volunteers
Interventions
REGN13335Drug
Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose
Matching PlaceboDrug
Administered IV or SC, sequential ascending single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events (TEAE's) through the end of the study (EOS) visitTime frame: Baseline to day 113
- Severity of TEAE's through the EOS visitTime frame: Baseline to day 113
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research
Christchurch, Canterbury, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.